SARS-CoV-2 nanobodies—microscopic molecules developed
at the University of Pittsburgh School of Medicine that neutralize
the virus in animals—are remarkably active against mutations found
in variants, including Delta, according to new research by Pitt and
Case Western Reserve University scientists.